Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC)

BACKGROUND: CXCR1 is recognized as an actionable receptor selectively expressed by breast cancer stem cells (BCSC). Reparixin is an investigational allosteric inhibitor of chemokine receptors 1 and 2 (CXCR1/2), and demonstrates activity against BCSC in human breast cancer xenografts. This Phase Ib c...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Cancer Res
Hoofdauteurs: Schott, Anne F., Goldstein, Lori J., Cristofanilli, Massimo, Ruffini, Pier Adelchi, McCanna, Susan, Reuben, James M., Perez, Raymond P., Kato, Giraldo, Wicha, Max
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2017
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600824/
https://ncbi.nlm.nih.gov/pubmed/28539464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2748
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items